Human Disease Phenotypes Associated With Mutations in TREX1

Journal of Clinical Immunology

Volumn 35, Issue 3, 2015, Pages 235-243

  Rice, Gillian I ^a   Rodero, Mathieu P ^b   Crow, Yanick J ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSERM   (France)

Author keywords

Aicardi Gouti res syndrome; Familial chilblain lupus; Retinal vasculopathy with cerebral leukodystrophy; Systemic lupus erythematosus; TREX1

Indexed keywords

EXONUCLEASE; THREE PRIME REPAIR EXONUCLEASE I; UNCLASSIFIED DRUG; EXODEOXYRIBONUCLEASE; PHOSPHOPROTEIN; THREE PRIME REPAIR EXONUCLEASE 1;

AICARDI GOUTIERES SYNDROME; CEREBRAL LEUKODYSTROPHY; CHILBLAIN; CLINICAL FEATURE; FAMILIAL CHILBLAIN LUPUS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LEUKODYSTROPHY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RETINA DISEASE; RETINAL VASCULOPATHY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; ANIMAL; DEMYELINATING DISEASE; GENETICS; MUTATION; NERVOUS SYSTEM MALFORMATION; NEUROLOGIC DISEASE; SKIN LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CHILBLAINS; EXODEOXYRIBONUCLEASES; HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MUTATION; NERVOUS SYSTEM MALFORMATIONS; PHENOTYPE; PHOSPHOPROTEINS; RETINAL DISEASES; VASCULAR DISEASES;

EID: 84925501444     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-015-0147-3     Document Type: Review

References (75)

1. Lindahl T, Gally JA, Edelman GM. Properties of deoxyribonuclease 3 from mammalian tissues. J Biol Chem. 1969;244(18):5014–9.
2. Perrino FW, Mazur DJ, Ward H, Harvey S. Exonucleases and the incorporation of aranucleotides into DNA. Cell Biochem Biophys. 1999;30(3):331–52.
3. Hoss M, Robins P, Naven TJ, Pappin DJ, Sgouros J, Lindahl T. A human DNA editing enzyme homologous to the escherichia coli DnaQ/MutD protein. EMBO J. 1999;18(13):3868–75.
4. Mazur DJ, Perrino FW. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3’– > 5’ exonucleases. J Biol Chem. 1999;274(28):19655–60.
5. Morita M, Stamp G, Robins P, Dulic A, Rosewell I, Hrivnak G, et al. Gene-targeted mice lacking the Trex1 (DNase III) 3’– > 5’ DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol. 2004;24(15):6719–27.
6. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol. 2010;11(11):1005–13.
7. Geijtenbeek TB. Host DNase TREX1 hides HIV from DNA sensors. Nat Immunol. 2010;11(11):979–80.
8. Hasan M, Yan N. Safeguard against DNA sensing: the role of TREX1 in HIV-1 infection and autoimmune diseases. Front Microbiol. 2014;5:193.
9. Abe J, Nakamura K, Nishikomori R, Kato M, Mitsuiki N, Izawa K, et al. A nationwide survey of aicardi-goutieres syndrome patients identifies a strong association between dominant TREX1 mutations and chilblain lesions: Japanese cohort study. Rheumatology (Oxford). 2014;53(3):448–58.
10. Rice G, Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J, et al. Clinical and molecular phenotype of aicardi-goutieres syndrome. Am J Hum Genet. 2007;81(4):713–25.
11. Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GM, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015;167(2):296–312.
12. Orebaugh CD, Fye JM, Harvey S, Hollis T, Perrino FW. The TREX1 exonuclease R114H mutation in aicardi-goutieres syndrome and lupus reveals dimeric structure requirements for DNA degradation activity. J Biol Chem. 2011;286(46):40246–54.
13. Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M, et al. Mutations in the gene encoding the 3’-5’ DNA exonuclease TREX1 cause aicardi-goutieres syndrome at the AGS1 locus. Nat Genet. 2006;38(8):917–20.
14. Lehtinen DA, Harvey S, Mulcahy MJ, Hollis T, Perrino FW. The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. J Biol Chem. 2008;283(46):31649–56.
15. Haaxma CA, Crow YJ, van Steensel MA, Lammens MM, Rice GI, Verbeek MM, et al. A de novo p. Asp18Asn mutation in TREX1 in a patient with aicardi-goutieres syndrome. Am J Med Genet A. 2010;152A(10):2612–7.
16. Abe J, Izawa K, Nishikomori R, Awaya T, Kawai T, Yasumi T, et al. Heterozygous TREX1 p. Asp18Asn mutation can cause variable neurological symptoms in a family with aicardi-goutieres syndrome/familial chilblain lupus. Rheumatology (Oxford). 2013;52(2):406–8.
17. Tungler V, Silver RM, Walkenhorst H, Gunther C, Lee-Kirsch MA. Inherited or de novo mutation affecting aspartate 18 of TREX1 results in either familial chilblain lupus or aicardi-goutieres syndrome. Br J Dermatol. 2012;167(1):212–4.
18. Rice G, Newman WG, Dean J, Patrick T, Parmar R, Flintoff K, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant aicardi-goutieres syndrome. Am J Hum Genet. 2007;80(4):811–5.
19. Ramantani G, Kohlhase J, Hertzberg C, Innes AM, Engel K, Hunger S, et al. Expanding the phenotypic spectrum of lupus erythematosus in aicardi-goutieres syndrome. Arthritis Rheum. 2010;62(5):1469–77.
20. Lee-Kirsch MA, Chowdhury D, Harvey S, Gong M, Senenko L, Engel K, et al. A mutation in TREX1 that impairs susceptibility to granzyme a-mediated cell death underlies familial chilblain lupus. J Mol Me d (Berl). 2007;85(5):531–7.
21. Fye JM, Orebaugh CD, Coffin SR, Hollis T, Perrino FW. Dominant mutation of the TREX1 exonuclease gene in lupus and aicardi-goutieres syndrome. J Biol Chem. 2011;286(37):32373–82.
22. Bailey SL, Harvey S, Perrino FW, Hollis T. Defects in DNA degradation revealed in crystal structures of TREX1 exonuclease mutations linked to autoimmune disease. DNA Repair (Amst). 2012;11(1):65–73.
23. Fye JM, Coffin SR, Orebaugh CD, Hollis T, Perrino FW. The Arg-62 residues of the TREX1 exonuclease act across the dimer interface contributing to catalysis in the opposing protomers. J Biol Chem. 2014;289(16):11556–65.
24. Dale RC, Tang SP, Heckmatt JZ, Tatnall FM. Familial systemic lupus erythematosus and congenital infection-like syndrome. Neuropediatrics. 2000;31(3):155–8.
25. De Laet C, Goyens P, Christophe C, Ferster A, Mascart F, Dan B. Phenotypic overlap between infantile systemic lupus erythematosus and aicardi-goutieres syndrome. Neuropediatrics. 2005;36(6):399–402.
26. Crow YJ, Livingston JH. Aicardi-goutieres syndrome: an important Mendelian mimic of congenital infection. Dev Med Child Neurol. 2008;50(6):410–6.
27. Crow YJ, Zaki MS, Abdel-Hamid MS, Abdel-Salam G, Boespflug-Tanguy O, Cordeiro NJ, et al. Mutations in ADAR1, IFIH1, and RNASEH2B Presenting As Spastic Paraplegia. Neuropediatrics. 2014.
28. Jepps H, Seal S, Hattingh L, Crow YJ. The neonatal form of aicardi-goutieres syndrome masquerading as congenital infection. Early Hum Dev. 2008;84(12):783–5.
29. Rice GI, Forte GM, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case–control study. Lancet Neurol. 2013;12(12):1159–69.
30. Cuadrado E, Vanderver A, Brown KJ, Sandza A, Takanohashi A, Jansen MH, et al. Aicardi-Goutieres syndrome harbours abundant systemic and brain-reactive autoantibodies. Ann Rheum Dis. 2014.
31. Rasmussen M, Skullerud K, Bakke SJ, Lebon P, Jahnsen FL. Cerebral thrombotic microangiopathy and antiphospholipid antibodies in aicardi-goutieres syndrome–report of two sisters. Neuropediatrics. 2005;36(1):40–4.
32. Olivieri I, Cattalini M, Tonduti D, La Piana R, Uggetti C, Galli J, et al. Dysregulation of the immune system in aicardi-goutieres syndrome: another example in a TREX1-mutated patient. Lupus. 2013;22(10):1064–9.
33. Jarukitsopa S, Hoganson DD, Crowson CS, Sokumbi O, Davis MD, Michet CJ, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus in a predominantly white population in the United States. Arthritis care & research. 2014.
34. Hedrich CM, Fiebig B, Hauck FH, Sallmann S, Hahn G, Pfeiffer C, et al. Chilblain lupus erythematosus–a review of literature. Clin Rheumatol. 2008;27(8):949–54.
35. Lee-Kirsch MA, Gong M, Schulz H, Ruschendorf F, Stein A, Pfeiffer C, et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet. 2006;79(4):731–7.
36. Yamashiro K, Tanaka R, Li Y, Mikasa M, Hattori N. A TREX1 mutation causing cerebral vasculopathy in a patient with familial chilblain lupus. J Neurol. 2013;260(10):2653–5.
37. Sugiura K, Takeichi T, Kono M, Ito Y, Ogawa Y, Muro Y, et al. Severe chilblain lupus is associated with heterozygous missense mutations of catalytic amino acids or their adjacent mutations in the exonuclease domains of 3'-repair exonuclease 1. J Investig Dermatol. 2012;132(12):2855–7.
38. Gunther C, Berndt N, Wolf C, Lee-Kirsch MA. Familial Chilblain Lupus Due to a Novel Mutation in the Exonuclease III Domain of 3’ Repair Exonuclease 1 (TREX1). JAMA dermatology. 2014.
39. du Moulin M, Nurnberg P, Crow YJ, Rutsch F. Cerebral vasculopathy is a common feature in Aicardi-Goutieres syndrome associated with SAMHD1 mutations. Proc Natl Acad Sci U S A. 2011;108 (26):E232; author reply E3.
40. Ravenscroft JC, Suri M, Rice GI, Szynkiewicz M, Crow YJ. Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus. Am J Med Genet A. 2011;155A(1):235–7.
41. Gunther C, Hillebrand M, Brunk J, Lee-Kirsch MA. Systemic involvement in TREX1-associated familial chilblain lupus. J Am Acad Dermatol. 2013;69(4):e179–81.
42. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Stone DL, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911–20.
43. Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921–31.
44. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507–18.
45. Crow YJ, Casanova JL. STING-associated vasculopathy with onset in infancy–a new interferonopathy. N Engl J Med. 2014;371(6):568–71.
46. Peschke K, Friebe F, Zimmermann N, Wahlicht T, Schumann T, Achleitner M, et al. Deregulated type I IFN response in TREX1-associated familial chilblain lupus. J Invest Dermatol. 2014;134(5):1456–9.
47. Gunther C, Meurer M, Stein A, Viehweg A, Lee-Kirsch MA. Familial chilblain lupus–a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1. Dermatology. 2009;219(2):162–6.
48. Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, et al. Mutations in the gene encoding the 3’-5’ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39(9):1065–7.
49. Namjou B, Kothari PH, Kelly JA, Glenn SB, Ojwang JO, Adler A, et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011;12(4):270–9.
50. Barizzone N, Monti S, Mellone S, Godi M, Marchini M, Scorza R, et al. Rare variants in the TREX1 gene and susceptibility to autoimmune diseases. Biomed Res Int. 2013;2013:471703.
51. Ellyard JI, Jerjen R, Martin JL, Lee A, Field MA, Jiang SH, et al. Whole exome sequencing in early-onset cerebral SLE identifies a pathogenic variant in TREX1. Arthritis & rheumatology. 2014.
52. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610–5.
53. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–23.
54. Richards A, van den Maagdenberg AM, Jen JC, Kavanagh D, Bertram P, Spitzer D, et al. C-terminal truncations in human 3’-5’ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007;39(9):1068–70.
55. Mateen FJ, Krecke K, Younge BR, Ford AL, Shaikh A, Kothari PH, et al. Evolution of a tumor-like lesion in cerebroretinal vasculopathy and TREX1 mutation. Neurology. 2010;75(13):1211–3.
56. DiFrancesco JC, Novara F, Zuffardi O, Forlino A, Gioia R, Cossu F, et al. TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy. Neurol Sci. 2014.
57. Gruver AM, Schoenfield L, Coleman JF, Hajj-Ali R, Rodriguez ER, Tan CD. Novel ophthalmic pathology in an autopsy case of autosomal dominant retinal vasculopathy with cerebral leukodystrophy. J Neuroophthalmol Off J North Am Neuro-Ophthalmol Soc. 2011;31(1):20–4.
58. Schuh E, Ertl-Wagner B, Lohse P, Wolf W, Mann JF, Lee-Kirsch MA, et al. Multiple sclerosis-like lesions and type I interferon signature in a patient with RVCL. Neurology (R) neuroimmunology & neuroinflammation 2015 2 (1): e55.
59. Barth PG, Walter A, van Gelderen I. Aicardi-goutieres syndrome: a genetic microangiopathy? Acta Neuropathol. 1999;98(2):212–6.
60. Ramesh V, Bernardi B, Stafa A, Garone C, Franzoni E, Abinun M, et al. Intracerebral large artery disease in aicardi-goutieres syndrome implicates SAMHD1 in vascular homeostasis. Dev Med Child Neurol. 2010;52(8):725–32.
61. Akwa Y, Hassett DE, Eloranta ML, Sandberg K, Masliah E, Powell H, et al. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol. 1998;161(9):5016–26.
62. Campbell IL, Krucker T, Steffensen S, Akwa Y, Powell HC, Lane T, et al. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res. 1999;835(1):46–61.
63. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Astrocytes produce interferon-alpha and CXCL10, but not IL-6 or CXCL8, in aicardi-goutieres syndrome. Glia. 2008;56(5):568–78.
64. Cuadrado E, Jansen MH, Anink J, De Filippis L, Vescovi AL, Watts C, et al. Chronic exposure of astrocytes to interferon-alpha reveals molecular changes related to aicardi-goutieres syndrome. Brain. 2013;136(Pt 1):245–58.
65. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–21.
66. Jen J, Cohen AH, Yue Q, Stout JT, Vinters HV, Nelson S, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology. 1997;49(5):1322–30.
67. Yang YG, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell. 2007;131(5):873–86.
68. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008;134(4):587–98.
69. Crow YJ, Rehwinkel J. Aicardi-goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum Mol Genet. 2009;18(R2):R130–6.
70. Stetson DB. Endogenous retroelements and autoimmune disease. Curr Opin Immunol. 2012;24(6):692–7.
71. Gall A, Treuting P, Elkon KB, Loo YM, Gale Jr M, Barber GN, et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity. 2012;36(1):120–31.
72. Volkman HE, Stetson DB. The enemy within: endogenous retroelements and autoimmune disease. Nat Immunol. 2014;15(5):415–22.
73. Ablasser A, Hemmerling I, Schmid-Burgk JL, Behrendt R, Roers A, Hornung V. TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. J Immunol. 2014;192(12):5993–7.
74. Hasan M, Koch J, Rakheja D, Pattnaik AK, Brugarolas J, Dozmorov I, et al. Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes. Nat Immunol. 2013;14(1):61–71.
75. Kavanagh D, Spitzer D, Kothari PH, Shaikh A, Liszewski MK, Richards A, et al. New roles for the major human 3’-5’ exonuclease TREX1 in human disease. Cell Cycle. 2008;7(12):1718–25.